

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The specification has also been amended to remove improper multiple dependencies and to place the application into better form for examination.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181

MSW/sll
1422-0514P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

7. (Amended) The therapeutic agent or prophylactic agent according to [any one of claims 1 to 6]claim 1, wherein the therapeutic agent or prophylactic agent is for oral administration.

1422-0514P-13 - GE24230E